1. Home
  2. VPG vs ADCT Comparison

VPG vs ADCT Comparison

Compare VPG & ADCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

VPG

Vishay Precision Group Inc.

HOLD

Current Price

$38.12

Market Cap

479.2M

Sector

Technology

ML Signal

HOLD

Logo ADC Therapeutics SA

ADCT

ADC Therapeutics SA

HOLD

Current Price

$4.25

Market Cap

496.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
VPG
ADCT
Founded
2009
2011
Country
United States
Switzerland
Employees
N/A
N/A
Industry
Electrical Products
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
479.2M
496.7M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
VPG
ADCT
Price
$38.12
$4.25
Analyst Decision
Strong Buy
Analyst Count
0
6
Target Price
N/A
$7.60
AVG Volume (30 Days)
121.6K
1.6M
Earning Date
11-04-2025
11-10-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.60
N/A
Revenue
$299,283,000.00
$75,209,000.00
Revenue This Year
$0.48
$10.36
Revenue Next Year
$4.94
$3.87
P/E Ratio
$63.45
N/A
Revenue Growth
N/A
6.35
52 Week Low
$18.57
$1.05
52 Week High
$39.86
$4.80

Technical Indicators

Market Signals
Indicator
VPG
ADCT
Relative Strength Index (RSI) 60.65 54.80
Support Level $36.36 $3.15
Resistance Level $39.86 $4.32
Average True Range (ATR) 1.57 0.38
MACD 0.40 0.03
Stochastic Oscillator 78.73 77.08

Price Performance

Historical Comparison
VPG
ADCT

About VPG Vishay Precision Group Inc.

Vishay Precision Group Inc manufactures and markets sensors, and sensor-based measurement systems, as well as specialty resistors and strain gages based on proprietary technology. The company provides precision products and solutions, many of which are designed-in by customers, specializing in the growing markets of stress, force, weight, pressure, and current measurements. The company reports in three product segments: Sensors segment, Weighing Solutions segment, and Measurement Systems segment. It has a business presence in the United States and other countries. It generates the maximum of its revenue from the United States.

About ADCT ADC Therapeutics SA

ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. In addition, it also has various other product candidates in its pipeline, such as ADCT-602, Claudin-6, PSMA, NaPi2b, and ASCT2. Geographically, the company generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).

Share on Social Networks: